Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8001 to 8050 of 8901 results

  1. The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40)

    This guidance has been updated and replaced by NICE technology appraisal guidance 187.

    Withdrawn guidance

  2. Guidance on the use of metal on metal hip resurfacing arthroplasty (TA44)

    This guidance has been updated and replaced by NICE technology appraisal guidance 304.

    Withdrawn guidance

  3. Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)

    This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.

    Withdrawn guidance

  4. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

    This guidance has been updated and replaced by NICE technology appraisal guidance 524.

    Withdrawn guidance

  5. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

    This guidance has been updated and replaced by NICE technology appraisal guidance 531.

    Withdrawn guidance

  6. Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (TA45)

    This guidance has been updated and replaced by NICE technology appraisal guidance 91.

    Withdrawn guidance

  7. Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)

    This advice has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  8. Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

    We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.

    Withdrawn guidance

  9. Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

    This guidance has been updated and replaced by NICE technology appraisal guidance 629.

    Withdrawn guidance

  10. Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (TA48)

    This guidance has been updated and replaced by NICE guideline NG107 

    Withdrawn guidance

  11. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655. 

    Withdrawn guidance

  12. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

    This guidance has been updated and replaced by NICE technology appraisal guidance 713.

    Withdrawn guidance

  13. Venetoclax for treating chronic lymphocytic leukaemia (TA487)

    This guidance has been updated and replaced by NICE technology appraisal guidance 796.

    Withdrawn guidance

  14. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

    This guidance has been updated and replaced by NICE technology appraisal guidance 653.

    Withdrawn guidance

  15. Human growth hormone for the treatment growth failure in children (TA42)

    This guidance has been updated and replaced by NICE technology appraisal guidance 188. 

    Withdrawn guidance

  16. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

    Withdrawn guidance

  17. Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.

    Withdrawn guidance

  18. IQoro for stroke-related dysphagia (MIB175)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.

    Withdrawn advice

  19. Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke (MIB141)

    This advice has been updated and replaced by NICE healthtech guidance 553.

    Withdrawn advice

  20. Curos disinfecting cap for needleless connectors (MIB143)

    This advice has been updated and replaced by NICE medical technologies guidance 44.

    Withdrawn advice

  21. UroShield for preventing catheter-associated urinary tract infections (MIB191)

    This advice has been updated and replaced by NICE healthtech guidance 620.

    Withdrawn advice

  22. Alpha-Stim AID for anxiety (MIB193)

    This advice has been updated and replaced by NICE healthtech guidance 570.

    Withdrawn advice

  23. DyeVert for reducing contrast media in coronary and peripheral angiography (MIB196)

    This advice has been updated and replaced by NICE healthtech guidance 594.

    Withdrawn advice

  24. Leukomed Sorbact for preventing surgical site infection (MIB197)

    This advice has been updated and replaced by NICE healthtech guidance 567.

    Withdrawn advice

  25. Prontosan for acute and chronic wounds (MIB220)

    This advice has been updated and replaced by NICE healthtech guidance 616.

    Withdrawn advice

  26. Point-of-care diagnostic testing in primary care for strep A infection in sore throat (MIB145)

    This advice has been updated and replaced by NICE HealthTech guidance 531.

    Withdrawn advice

  27. QAngio XA 3D/QFR imaging software for assessing coronary obstructions (MIB146)

    This advice has been updated and replaced by NICE healthtech guidance 571.

    Withdrawn advice

  28. PICO negative pressure wound therapy for closed surgical incision wounds (MIB149)

    This advice has been updated and replaced by NICE medical technologies guidance 43.

    Withdrawn advice

  29. Eyemax mono for age-related macular degeneration (MIB154)

    We’ve temporarily withdrawn this medtech innovation briefing to correct factual errors in the text.

    Withdrawn advice

  30. NephroCheck test to help assess the risk of acute kidney injury in critically ill patients (MIB156)

    This medtech innovation briefing has been updated and replaced by NICE HealthTech guidance 544.

    Withdrawn advice

  31. Rezum for treating benign prostatic hyperplasia (MIB158)

    This advice has been updated and replaced by NICE medical technologies guidance 49. 

    Withdrawn advice

  32. gammaCore for cluster headache (MIB162)

    This advice has been updated and replaced by NICE medical technologies guidance 46.

    Withdrawn advice

  33. Axonics sacral neuromodulation system for overactive bladder and faecal incontinence (MIB164)

    This advice has been updated and replaced by NICE medical technologies guidance 50.

    Withdrawn advice

  34. Cerebrotech Visor for detecting stroke (MIB165)

    The medtech innovation briefing on Cerebrotech Visor for detecting stroke has been withdrawn as the technology is no longer available in the NHS.

    Withdrawn advice

  35. The ZedScan as an adjunct to colposcopy in women with suspected cervical intra‑epithelial neoplasia (MIB20)

    This advice has been updated and replaced by NICE diagnostics guidance 32.

    Withdrawn advice

  36. Plus Sutures for preventing surgical site infection (MIB204)

    This advice has been updated and replaced by NICE healthtech guidance guidance 586.

    Withdrawn advice

  37. IQoro for hiatus hernia (MIB176)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.

    Withdrawn advice

  38. PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

    This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.

    Withdrawn advice

  39. LiverMultiScan for liver disease (MIB181)

    This advice has been updated and replaced by NICE healthtech guidance 655.

    Withdrawn advice

  40. SEM Scanner for pressure ulcer prevention (MIB182)

    This advice has been updated and replaced by NICE medical technologies guidance 51.

    Withdrawn advice

  41. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection.

    Withdrawn advice

  42. Danis stent for acute oesophageal variceal bleeds (MIB185)

    This advice has been updated and replaced by NICE healthtech guidance 574.

    Withdrawn advice

  43. Endo-SPONGE for colorectal anastomotic leakage (MIB188)

    This advice has been updated and replaced by NICE healthtech guidance 605.

    Withdrawn advice

  44. The V.A.C. Veraflo Therapy system for infected wounds (MIB189)

    This advice has been updated and replaced by NICE healthtech guidance 566.

    Withdrawn advice

  45. EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules (MIB209)

    This advice has been updated and replaced by NICE healthtech guidance 611.

    Withdrawn advice

  46. myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)

    This advice has been updated and replaced by NICE medical technologies guidance 68.

    Withdrawn advice

  47. Space from Depression for treating adults with depression (MIB215)

    This advice has been updated and replaced by NICE HealthTech guidance 675.

    Withdrawn advice

  48. FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)

    This advice has been updated and replaced by NICE healthtech guidance 682.

    Withdrawn advice

  49. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  50. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

    Withdrawn guidance